Clinical trial
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic…
NCT07015697 · Daiichi Sankyo, Industry · Recruiting
Key facts
| NCT number | NCT07015697 |
|---|---|
| Title | A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors |
| Official title | A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors |
| Lead sponsor | Daiichi Sankyo, Industry |
| Collaborators | AstraZeneca Industry |
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Recurrent or Metastatic Solid Tumors |
| Intervention type | Drug |
| Interventions | Trastuzumab Deruxtecan |
| Enrollment | 76 |
| Start date | Jul 17, 2025 |
| Primary completion | Dec 31, 2028 |
| Completion | Dec 31, 2028 |
| First posted | Jun 11, 2025 |
| Last update posted | Feb 10, 2026 |
| Countries | Japan, South Korea, Spain, Taiwan, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: